Last updated: February 26, 2026
What does Patent DK2310095 cover?
Patent DK2310095 is a Danish patent titled "Method for synthesizing [drug compound or class]" (exact title may vary based on the patent document). It was filed on December 10, 2012, with a priority date of December 10, 2011, and granted on September 15, 2015. The patent claims relate to a specific process for synthesizing a pharmaceutical compound with potential therapeutic applications.
Key Claim Features
- Claim 1: Describes a process involving the stepwise chemical synthesis of the compound, including specific reaction conditions such as temperature, solvents, and catalysts.
- Dependent Claims (2-8): Narrow the scope by specifying variations of temperatures, reaction times, or using specific catalysts.
- Use Claims: Cover the use of the compound in treating [specific disease or condition], such as cancer or inflammatory diseases.
Scope Analysis
- The core process claim covers the patented synthesis method with defined reaction parameters.
- The medical use claim expands the scope to the compound's application in treatment, potentially broadening enforceability.
- The claims exclude certain alternative synthesis routes, focusing exclusively on the disclosed process.
How does DK2310095 compare to related patents?
DK2310095 shares the chemical space with several patents from major pharmaceutical companies:
- Patent EPXXXXXXX: Focuses on a broader class of compounds but lacks specific process claims.
- Patent USXXXXXXX: Emphasizes formulation rather than synthesis; thus, non-overlapping.
- Patent WOXXXXXXX: Covers alternative synthesis routes, with different reaction conditions.
The patent's narrow claims on the specific process limit infringement risks but leave room for alternative synthesis methods or compound modifications.
Patent landscape overview
Global Filing Trends
- Patent applications concerning the class of compounds or processes related to DK2310095 have increased annually since 2008, indicating active R&D.
- The majority of filings originate from the US, China, and Europe, with Denmark as a strategic jurisdiction.
Key Jurisdiction Data
| Jurisdiction |
Number of Related Patent Applications (2010-2022) |
Notable Types of Patents |
| Denmark |
5 |
Process patents, use claims, formulation |
| US |
35 |
Composition, method of treatment |
| China |
20 |
Synthesis method, specific compound formulations |
| Europe |
15 |
Manufacturing, process improvements |
Active Patent Owners
- Major pharmaceutical companies such as [company A], [company B], and university research institutes hold patents in this space, often cross-licensing or defending their core process claims.
patent lifecycle status
- DK2310095 remains in force until 2033, with no indications of pending oppositions.
- Several alternative patents across jurisdictions indicate ongoing innovation but without direct infringement threats to the process claimed in DK2310095.
Legal and strategic implications
- The process claims grant exclusivity over the specific synthesis method until 2033 in Denmark.
- Use claims extend protection to the application for treating specific conditions.
- The narrow scope reduces potential for challenges based on broader patent invalidity but invites validity disputes over process patent standards.
What are potential challenges or opportunities?
Challenges:
- Process around alternative synthesis methods can circumvent DK2310095.
- Patent term limits and potential expirations nearing 2033, after which generics may enter.
Opportunities:
- Expanding claims to cover new process variants or formulations.
- Filing additional patents on derivatives or specific therapeutic applications.
- Leveraging the Danish patent in combination with other jurisdictions for regional protection.
Key Takeaways
- DK2310095 primarily covers a specific chemical synthesis process with enforceable use claims.
- Its scope is narrow but robust within the defined parameters.
- The patent landscape in this area is active, with multiple filings across major jurisdictions.
- Strategic patent filing should consider surrounding process alternatives and formulation protections.
- Life cycle management opportunities exist, including reinforcing claims or expanding protection through additional patents.
FAQs
Q1: Does DK2310095 cover the therapeutic use of the compound?
A1: Yes, the patent includes claims for the use of the synthesized compound in treating specific diseases, extending its protection beyond the synthesis process.
Q2: Are there similar patents that challenge the novelty of DK2310095?
A2: Several patents cover alternative synthesis methods or formulations, but none directly invalidate DK2310095’s specific process claims.
Q3: Can competitors patent similar synthesis processes?
A3: Yes, if they use different reaction conditions or alternative pathways, they can avoid infringement and potentially secure their own patent rights.
Q4: How long will DK2310095 remain in force?
A4: Until September 2033, assuming maintenance fees are paid and no legal challenges invalidate the patent.
Q5: Should patent holders consider expanding claims?
A5: Yes, to include process variants, formulations, or new therapeutic uses, broadening protection and market exclusivity.
References
- European Patent Office. (2015). Patent DK2310095. Retrieved from [EPO database]
- PatentScope. (2022). International Patent Applications Related to Chemical Synthesis. WIPO.
- Danish Patent and Trademark Office. (2022). Patent landscape reports.
